Gut-derived glucagon-like peptides attenuate T cell-induced intestinal injury.
Semaglutide isn’t just a hot topic in metabolic research — it’s now showing promise for gut health, too. A new study from the University of Toronto throws down some clear evidence: glucagon-like peptides, including GLP-1 analogs like semaglutide, protect the intestine from T cell-induced damage.
Cell Rep Med
by Koehler JA, Baggio LL, Cao X et al.
“Gut-derived glucagon-like peptides attenuate T cell-induced intestinal injury. Koehler JA(1), Baggio LL(1), Cao X(1), Shang R(1), Yusta B(1), Wong CK(2), Matthews D(1), Sandoval DA(3), Drucker DJ(4). Author information: (1)Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON M5G1X5, Canada. (2)Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON M5G1X5, Canada; MRC Laboratory of Medical Sciences, London, UK. (3)Department of Pediatrics and Medicine, University of Colorado Anschutz, Medical Campus, Aurora, CO 80045, USA. (4)Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, ON M5G1X5, Canada. Electronic address: drucker@lunenfeld.ca. Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are produced in enteroendocrine L cells and control energy homeostasis. GLP-1 receptor (GLP-1R) activation improves glucose homeostasis and induces satiety and weight loss, whereas GLP-2 receptor (GLP-2R) signaling promotes intestinal growth and nutrient absorption. GLP-1R and GLP-2R agonism also reduce intestinal damage in preclinical studies. Here, we demonstrate that endogenous GLP-1R and GLP-2R signaling are essential for protecting the intestine from T cell-mediated enteropathy. Gut injury induced by T cell activation is increased in Glp1r-/- and Glp2r-/- mice, as well as in mice with selective loss of intestinal proglucagon gene expression (GcgGut-/-). Conversely, the GLP-2R agonist teduglutide and the GLP-1R agonist semaglutide, administered separately or together, attenuate αCD3-induced intestinal damage in GcgGut-/- mice. Collectively, these findings demonstrate distinct biological roles for endogenous GLP-1R/GLP-2R activity in immune-mediated intestinal injury and highlight the therapeutic potential of glucagon-like peptides, alone or together, for ameliorating T cell-mediated mucosal injury. Copyright © 2026 The Author(s). Published by Elsevier Inc. All rights reserved. Conflict of interest statement: Declaration of interests D.J.D. has received consulting fees from Amgen, AstraZeneca Inc., Crinetics Pharmaceuticals Inc., Eli Lilly Inc., General Medicines, Kallyope, Metsera, Pfizer Inc., Protagonist Therapeutics, Roche, and Sanofi and speaking fees from Novo Nordisk Inc. Mt. Sinai Hospital has received investigator-initiated grant support from Amgen, Eli Lilly Inc., and Zealand Pharmaceuticals Inc. to support preclinical studies in the Drucker lab unrelated to the current studies. The University of Toronto, the University Health Network, and Takeda are parties to a license agreement surrounding the use of teduglutide for short bowel syndrome.”
The science is straightforward. GLP-1 and GLP-2 are hormones made in the gut. They do more than regulate blood sugar and appetite. When researchers knocked out GLP-1 and GLP-2 signaling in mice, those animals got way more gut injury from immune attacks. Bring back the peptides — either semaglutide for GLP-1 or teduglutide for GLP-2 — and the damage drops. Even more interesting, the peptides worked whether given alone or together.
Key takeaway: Gut-derived peptides aren’t just metabolic switches. They’re also critical for keeping the intestinal lining safe during immune stress.
For peptide researchers, this opens up new questions:
Can combining GLP-1 and GLP-2 analogs offer even stronger gut protection?
How does this immune-modulating effect translate to human models?
What’s the best protocol for leveraging these peptides in immune research?
It’s another reason to keep an eye on semaglutide research. The peptide’s role keeps expanding beyond traditional glucose and appetite studies. If you’re exploring gut-immune interactions, this is a signal to dig deeper into GLP-1 and GLP-2 analogs. For sourcing these research compounds, check out the semaglutide page or compare suppliers in our vendor directory.
This isn’t just another metabolic pathway story. The gut is a battleground, and peptides like semaglutide are proving to be serious contenders in protecting intestinal health.
Related Reading
Periocular surgery risk after glucagon-like peptide-1 receptor agonist therapy for type 2 diabetes.
News · OMICSOral Versus Injectable Incretin-Based Anti-Obesity Therapies: An Integrated Computational and Evidence-Based Comparison of Orforglipron, Semaglutide, and Tirzepatide.
News · Mol Cell ProteomicsThe soluble HLA repertoire captures neoantigenic, cryptic, and tumour-associated peptides in melanoma.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.